Selecta Biosciences Inc., of Watertown, Mass., has filed with the SEC to offer 4.25 million shares, priced between $14 and $16 each in an IPO. The company said it is using synthetic vaccine particle technology to discover and develop targeted therapies that are designed to modulate the immune system to effectively and safely treat rare and serious diseases. They have applied to list their common stock on the Nasdaq Global Market under the symbol SELB.